$4.29
+0.37 (+9.44%)
Open$4.03
Previous Close$3.92
Day High$4.35
Day Low$4.01
52W High$22.76
52W Low$12.16
Volume—
Avg Volume782.8K
Market Cap50.53M
P/E Ratio18.53
EPS$0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+339.6% upside
Current
$4.29
$4.29
Target
$18.86
$18.86
$15.04
$18.86 avg
$28.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.73M | 28.89M | 22.68M |
| Net Income | 2.46M | 2.55M | 2.38M |
| Profit Margin | 8.9% | 8.8% | 10.5% |
| EBITDA | 4.02M | 4.88M | 3.72M |
| Free Cash Flow | 2.55M | 2.44M | 2.81M |
| Rev Growth | +8.3% | +0.1% | +7.6% |
| Debt/Equity | 0.57 | 0.72 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |